HR19042
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
September 23, 2025
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
(clinicaltrials.gov)
- P2 | N=316 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting | N=210 ➔ 316 | Trial completion date: May 2024 ➔ Nov 2025 | Trial primary completion date: Feb 2024 ➔ Nov 2025
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Glomerulonephritis • IgA Nephropathy • Renal Disease
September 12, 2025
Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects.
(PubMed, Clin Pharmacol Drug Dev)
- "The Cmax of HR19042 was approximately 1.9-fold higher than that of Nefecon and 1.4-fold higher than that of Budenofalk. In vitro, the dissolution of HR19042 occurred 30 min earlier than that of Nefecon in the intestinal buffer medium. In conclusion, both in vivo and in vitro findings suggest that HR19042 exhibits a faster absorption rate and higher oral bioavailability."
Journal • PK/PD data • Glomerulonephritis • IgA Nephropathy • Renal Disease
April 11, 2025
Relative Bioavailability Study of HR19042 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=18 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Autoimmune Hepatitis • Glomerulonephritis • Hepatology • IgA Nephropathy • Immunology • Inflammation • Renal Disease
March 24, 2025
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
(clinicaltrials.gov)
- P2 | N=69 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2023 ➔ Mar 2025
Trial completion • Trial completion date • Trial primary completion date • Autoimmune Hepatitis • Hepatology • Immunology • Inflammation
August 21, 2023
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
(clinicaltrials.gov)
- P2 | N=81 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Autoimmune Hepatitis • Hepatology • Immunology • Inflammation
July 27, 2022
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
(clinicaltrials.gov)
- P2 | N=81 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Hepatology • Immunology • Inflammation
October 12, 2021
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
(clinicaltrials.gov)
- P2; N=210; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease
September 24, 2021
A Trial of HR19042 Capsule in Healthy Chinese Subjects
(clinicaltrials.gov)
- P1; N=12; Completed; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Completed
Trial completion • Glomerulonephritis • IgA Nephropathy • Renal Disease
August 23, 2021
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
(clinicaltrials.gov)
- P2; N=210; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
May 14, 2021
A Trial of HR19042 Capsule in Healthy Chinese Subjects
(clinicaltrials.gov)
- P1; N=12; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • New P1 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
1 to 10
Of
10
Go to page
1